Changes in Hong Kong stocks | Kangchen Pharmaceutical (01681) is now up more than 6%, and the company continues to have high dividend returns, shareholder organizations say the annual dividend rate is expected to exceed 10%

The Zhitong Finance App learned that Kangchen Pharmaceutical (01681) is now up more than 6%, with an intraday high of HK$8.29, a record high. As of press release, it rose 5.74% to HK$8.11, with a turnover of HK$446.813 million.

According to Anxin International, Kangchen Pharmaceutical achieved revenue and net profit of 1.27 billion yuan and 40 billion yuan respectively in the first half of the year, up 13.3% and 14.9% year-on-year respectively, mainly driven by the women and children and imaging sectors. The gross margin remained at 74.7%, and the net margin increased slightly by 0.4 percentage points to 31.5%. The company continues to pay high dividends to shareholders, with a cumulative dividend payment of over HK$2.4 billion, and a year-round dividend ratio of over 30%.

Cinda Securities, on the other hand, stated that in May '24, the company declared a special dividend of HK$0.3 per share to celebrate the 10th anniversary of its listing on the main board of the Hong Kong Stock Exchange. Assuming that the company still declared a dividend of HK$0.3 per share at the end of '24, the dividend ratio corresponding to the current market value in '24 is expected to be 14.92%. If the company does not declare a dividend at the end of '24, compiling the special dividend and interim dividend, the dividend ratio corresponding to the current market value in '24 is expected to be 9.95%.